Regulus jumps after data from early-stage trial for kidney disease therapy (update)
Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...
American Association of Individual Investors2d
Why Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 12.00%
Regulus Therapeutics Inc.’s RGLS share price has surged by 12.00%, which has investors questioning if this is right time to sell.
Fintel on MSN7d
Wells Fargo Upgrades Regulus Therapeutics (RGLS)
Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal ...
Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)
Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to Overweight
Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an ...
Seeking Alpha7d
Regulus jumps after data from early-stage trial for kidney disease therapy (update)
Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...
Yahoo Finance17d
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now
In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs ...